STUDY SYNOPSIS:
Compared efficacy and safety of 2 treatment modalities in
patients with vitiligo. Study was a before-and-after trial with
2 arms, involving 99 men and 182 women with predominately skin
type III and generalized vitiligo of at least 3 months'
duration. 46% of first PUVA treatment group showed
repigmentation after four months. 67% of of 311-nm treatment
group showed repigmentation after four months.
STUDY CONCLUSION: According to results, the treatment of patients with
vitiligo with 311-nm UV-B radiation is as efficient as with
topical PUVA and has fewer adverse effects.
Journal of American Academy of Dermatology
VOL 42, Number 2, Part 1. February 2000
STUDY SYNPOSIS: Studied efficacy and safety of UVB (311 nm) therapy in
children with generalized vitiligo. 51 Children were treated
twice a week for one year. Psychosocial impact of disease and
treatment were carefully evaluated before and after. 75% overall
repigmentation in 53% of patients and a stabilization of the
disease in 80%.
STUDY CONCLUSION: Narrow-band UVB therapy is effective and safe in childhood
vitiligo; it may also significantly improve the quality of life.
By: Lubomira Scherschun, MD; Jane J. Kim, MD; Henry W. Lim, MD
Journal of American Academy of Dermatology
VOL 44, Number 6. June 2001
STUDY SYNOPSIS: Seven diverse vitiligo patients treated for one year with
narrow-band UVB therapy. Five of the seven achieved 75%
repigmentation with a mean of 19 treatments.
STUDY CONCLUSION: Treatment protocol resulted in rapid repigmentation in many
patients, including those with skin phototypes IV and V. In
accordance with previous studies, this report indicates that
narrow-band UVB is a useful and well-tolerated therapy for
vitiligo.
By: Ian B. Walters, MD; Lauren H. Burack, MD; Todd R. Coven, MD;
Patricia Gilleaudeau, RN, BSN; James G. Krueger, MD, PhD
Journal of the American Academy of Dermatology
VOL 40, Number 6, Part 1. June 1999
STUDY SYNOPSIS: Eleven patients treated using split-body approach, three
times a week, for six weeks. Able to induce clinical clearing in
81.8% of patients after NB-UVB, but only 9.1% after BB-UVB.
STUDY CONCLUSION: NB-UVB is superior to UVB-BB in reversing psoriasis at
suberythemogenic doses when given three times per week. This
schedule was well tolerated by all patients.
By: Todd R. Coven, MD; Lauren H. Burack, MD; Patricia
Gilleaudeau, RN, BSN; Mary Keogh, RN, MSN; Maki Ozawa, MD; James
G. Krueger, MD, PhD
Archives of Dermatology
VOL 133, December 1997
STUDY SYNOPSIS: 22 patients treated over four week span to compare
therapeutic effectiveness of daily exposure to narrowband (NB)
UV-B vs broadband (BB) UV-B with and without tar. Clinical
resolution of psoriasis was achieved on 86% of paired sites
treated with NB UV-B, compared to 73% with BB UV-B.
Histopathological resolution of epidermal hyperplasia was
achieved in 88% of lesions treated with NB UV-B, compared with
59% with BB UV-B.
STUDY CONCLUSION: Narrowband UV-B offers a significant therapeutic advantage
over BB UV-B in the treatment of psoriasis, with faster clearing
and more complete disease resolution. The erythema response to
NB UV-B treatment was significantly more intense and persistent
compared with BB UV-B. Considerably more necrotic keratinocytes
were observed in histopathological sections of skin treated with
NB UV-B after a single 2.0- minimum erythema dose exposure.
Treatment should be coupled with obligate minimum erythema dose
testing to NB UV-B and close clinical observation during dose
increases.
By: P. M. Gordon, MRCP; B. L. Diffey, PhD; J. N. S. Matthews,
PhD; and P. M. Farr, MD
Journal of American Academy of Dermatology
VOL 41, Number 5, Part 1. November 1999
STUDY SYNOPSIS: 100 patients were randomly allocated with twice-weekly
treatments with PUVA or narrow-band UVB. Clearance of psoriasis
was achieved in 84% of PUVA patients vs 63% with TL-01. Plus,
the PUVA success took significantly fewer treatments.
STUDY CONCLUSION: When given twice weekly, PUVA is more effective for
psoriasis than narrow-band UVB phototherapy.
By: Colin Clark, MRCP; Robert S. Dawe, MRCP; Alan T. Evans,
MRCPath; Graham Lowe, FRCP; James Ferguson, FRCP
Archives of Dermatology
VOL 136, June 2000
STUDY SYNOPSIS: Eight patients with patch-stage MF received TL-01
phototherapy 3 times weekly using standard protocol. Complete
clearance of MF achieved in 6 cases in a mean of 9 weeks. 4
patients have had prolonged remissions.
STUDY CONCLUSION: TL-01 is an effective, convenient therapy that may have less
risk of long-term adverse effects than current alternatives.
Although larger prospective studies are necessary, for some
patients intermittent courses of TL-01 may offer effective
long-term
